

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1430 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/849,825	05/21/2004	Nadia Gardel	119740	8388
92793 7590 03/90/2010 Oliff & Berridge, PLC P.O. Box 320850 Alexandria, VA 22/320-4850			EXAMINER	
			FRAZIER, BARBARA S	
Alexandria, VA 22320-4630			ART UNIT	PAPER NUMBER
			1611	
			NOTIFICATION DATE	DELIVERY MODE
			03/30/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

OfficeAction92793@oliff.com jarmstrong@oliff.com

Application No. Applicant(s) 10/849.825 GARDEL ET AL. Office Action Summary Examiner Art Unit BARBARA FRAZIER 1611 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 17 December 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-4.6-52 and 54-104 is/are pending in the application. 4a) Of the above claim(s) 31-39.43-47.86-94.98-102 and 104 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-4,6-30,40-42,48-52,54-85,95-97 and 103 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date

Notice of Draftsperson's Patent Drawing Preview (PTO-948).

3) Information Disclosure Statement(s) (PTO/SB/08)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/849,825 Page 2

Art Unit: 1611

DETAILED ACTION

Status of Claims

- 1. Claims 1-4, 6-52, and 54-109 are pending in this application.
- Claims 31-39, 43-47, 86-94, 98-102, and 104 remain withdrawn from further
 consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected subject
 matter, there being no allowable generic or linking claim. Applicant timely traversed the
 restriction (election) requirement in the reply filed on 7/18/07.
- Claims 1-4, 6-30, 40-42, 48-52, 54-85, 95-97, and 103 are examined.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 1-4, 6-30, 40-42, 48-52, 54-85, 95-97, and 103 are rejected under 35
 U.S.C. 103(a) as being unpatentable over Hanna et al (US Patent 5,843,417) in view of Hansenne et al (US Patent 6,432,389) and Lebreton (US Patent 6,207,175).

The claimed invention is drawn to a fluid cosmetic composition in the form of a water-in-oil emulsion comprising a liquid fatty phase, an aqueous phase, a dimethicone copolyol and solid particles of polymethyl methacrylate, the liquid fatty phase comprising isododecane and the composition being free of cyclotetrasiloxane, wherein the solid

Art Unit: 1611

particles of polymethyl methacrylate comprise at least two polymethyl methacrylates having different densities (see claim 1).

Hanna et al teach a water-in-oil (W/O) emulsion, wherein the oil is preferably a C10-C14 saturated, linear, or branched hydrocarbon such as isododecane (col. 1, lines 49-54). The emulsion contains one or more surfactants such as dimethicone copolyol, lauryl methicone copolyol, and cetyl dimethicone copolyol (col. 5, lines 3-5). The W/O emulsion preferably contains a water-soluble and/or water-dispersible polymer, and may also contain various ingredients common in the cosmetics art, including fillers and sunscreens (col. 2, lines 4-12 and col. 6, lines 66-67). The compositions are cosmetic products, which may be used on the skin, such as a liquid foundation, concealer, or blush (col. 1, lines 34-35). The composition may also contain other oils commonly used in cosmetic emulsions such as silicone oils, including volatile silicone oils such as linear and cyclic silicone oils (col. 3, lines 33-35) and does not contain cyclotetrasiloxane.

Hanna et al do not specifically teach the presence of polymethyl methacrylate particles in the composition.

Hansenne et al teach a topically cosmetic/dermatological composition well suited for the UV-photoprotection of human skin, comprising an effective UV-photoprotecting amount of a t least one UV-A and/or UV-B sunscreen, and an amount of a methyl methacrylate crosspolymer, formulated into a topically applicable, cosmetically/dermatologically acceptable vehicle (abstract). An example of the particulates of methyl methacrylate crosspolymer is Jurymer MB-1P (col. 2, line 66 - col. 3, line 5). It is noted that this particle is also exemplified by Applicants as being suitable

Art Unit: 1611

for the claimed invention; see paragraph 23 and Example 1, paragraph 132 of Applicant's specification. The methyl methacrylate crosspolymer provides the benefits of reducing the greasiness and improving the dryness of the formulation (abstract and col. 2, lines 30-35). The compositions can be formulated into a wide variety of product types, including water-in-oil emulsions (col. 7, lines 34-36). Hansenne et al further teach that a variety of additional components can also be incorporated into the composition (col. 9, lines 55-64).

Lebreton teach powdered cosmetic and/or dermatological lotion comprising a powdered phase comprising at least one active powder and hollow particles based on at least one acrylic or methacrylic polymer or copolymer (abstract). The active powder may be a protective powder, for example, for UV protection (col. 3, lines 10-11). The addition of the hollow particles based on methacrylic polymer allows for a powdered phase which does not become clogged, while being soft on application, (col. 1, lines 63-66). Examples of hollow particles include poly(methyl methacrylate) particles, such as "Covabead LH 85" (col. 3, lines 42-45). It is noted that this particle is also exemplified by Applicants as being suitable for the claimed invention; see paragraph 23 and Example 1, paragraph 131 of Applicant's specification.

It is further noted that "Jurymer MB1" and "Covabead LH 85" are examples of two polymethyl methacrylates having different densities, as evidenced by Applicant's specification (see paragraph 23 and Example 1 of Applicant's specification).

It would have been obvious to a person having ordinary skill in the art at the time the invention was made to add UV formulations comprising methyl methacrylate

Art Unit: 1611

crosspolymer and hollow particles of poly(methyl methacrylate) (i.e., two polymethyl methacrylates having different densities) to the formulation of Hanna et al; thus arriving at the claimed invention. One skilled in the art would be motivated to add the UV formulation comprising methyl methacrylate crosspolymer to the formulation of Hanna et al because said addition provides the benefits of reducing the greasiness and improving the dryness of the formulation, as taught by Hansenne et al. One would reasonably expect success from said addition because Hanna et al teach that its formulations may include various ingredients common in the cosmetics art, including sunscreens, and because Hansenne et al teach that compositions can be formulated into a wide variety of product types, including water-in-oil emulsions. Additionally, one skilled in the art would be motivated to add hollow particles of poly(methyl methacrylates) to the methyl methacrylate crosspolymer composition of Hansenne et al because the addition of said hollow particles to an active powder formulation provides the benefits of a powdered phase which does not become cloqged, while being soft on application, as taught by Lebreton. One would reasonably expect success from said addition because Lebreton teaches that the active powders, to which its hollow particles are added, include protective powders such as UV protection, and because Hansenne et al teach that a variety of additional components can also be incorporated into its composition.

Regarding the density ranges and differing densities of two polymethyl methacrylates (claims 2-4, 6-12, 50-52, and 54-60), it is noted that the polymethyl methacrylates taught by Hansenne et al and Lebreton (i.e., Jurymer MB1-P and Covabead LH 85) are the same as those exemplified by Applicants, and therefore would

Art Unit: 1611

necessarily have the same density ranges and differing densities as the claimed invention.

Regarding the amount of polymethyl methacrylate (claims 13-15 and 61-63),
Hansenne et al exemplify amounts of methyl methacrylate crosspolymer of 3-5%
(Examples 1 and 2), and Lebreton teaches amounts of hollow particles more preferably ranging from 0.1 to 5% (col. 4, lines 11-15). These amounts are comparable to those of the claimed invention; one skilled in the art would be motivated to select amounts from within said ranges by routine experimentation, in order to optimize properties of the resultant composition, such as flowability and skin feel.

Regarding the dimethicone copolyol (claims 16-20 and 64-68), Hanna et al teach the presence of dimethicone copolyol in the W/O emulsion (col. 5, lines 3-5).

Regarding the amount of dimethicone copolyol (claims 21 and 69), Hanna et al teach that the amount of oil surfactant useful in the W/O emulsion is most preferably 8-10 wt.% (col. 5, lines 29-33). This is comparable to Applicant's amount of from 5% to 10% by weight.

Regarding the amount of isododecane or volatile hydrocarbon based oil (claims 22-24 and 77-79), Hanna et al teach that the W/O emulsion preferably contains 10-55% oil (col. 2, lines 62-65). These amounts overlap those of the claimed invention, and one skilled in the art would be motivated to select amounts of isododecane from within said ranges by routine experimentation, in order to optimize the stability of the resultant emulsion.

Art Unit: 1611

Regarding the additional volatile oil (claims 25-30 and 80-85), Hanna et al teach that the composition may also contain other oils commonly used in cosmetic emulsions such as silicone oils, including volatile silicone oils such as linear and cyclic silicone oils (col. 3, lines 33-35). Bara teaches that silicone oils such as decamethylcyclopentasiloxane are known to be used in W/O emulsions for making up the skin (col. 3, lines 33-42). Thus, it would have been within the purview of the skilled artisan to select silicone oils such as decamethylcyclopentasiloxane as the silicone oils taught by Hanna et al. Additionally, Hanna et al teach that oil is 10-55% of the composition, and the silicone oil is 0-50% of the oil (col. 2, lines 62-63 and col. 3, lines 37-42). Therefore, the amount of additional volatile oil is 0-27.5%. This amount range overlaps those of the claimed invention, and one skilled in the art would have been motivated to manipulate the amount of additional oil present by routine experimentation, in order to optimize the desired feel and behavior of the composition, as taught by Hanna et al (col. 3, lines 37-38).

Regarding the aqueous phase (claims 40-42 and 95-97), Hanna et al teach that solid particles are present in the emulsion (col. 3, lines 45-49), and therefore water-dispersible compounds are present in the aqueous phase. Additionally, Hanna et al teach that the aqueous phase is present in an amount ranging more preferably from 30 to 50% by weight (col. 2, lines 37-38). This amount is comparable to or overlaps that of the claimed invention, and one skilled in the art would be motivated to select amounts of isododecane from within said ranges by routine experimentation, in order to optimize the stability of the resultant emulsion.

Art Unit: 1611

Regarding the form of the composition (claims 48 and 103), Hanna et al teach that the composition is in the form of a skin makeup composition (for example, see col. 7, Example).

Regarding the C₈-C₂₂ alkyl dimethicone copolyol (claims 49 and 70-74), Hanna et al teach the presence of cetyl dimethicone copolyol in the W/O emulsion (col. 5, line 5), in an amount of 5-15% (col. 5, lines 29-33). This amount is comparable to Applicant's amounts, and it would be within the purview of the skilled artisan to adjust the amount of surfactant by routine experimentation, in order to optimize the stability of the resultant emulsion.

Regarding the volatile hydrocarbon-based oil (claims 49, 75, and 76), Hanna et al teach that isododecane is present in the W/O emulsion (col. 1, lines 49-55).

Response to Arguments

 Applicant's arguments filed 12/17/09 have been fully considered but they are not persuasive.

Applicants argue that the teachings of Hansenne are directed to the addition of a methyl methacrylate crosspolymer effective to reduce the greasiness and diffusion of the sunscreen compositions, as well as to improve the dryness of the sunscreen compositions. Applicants argue that an ordinarily skilled artisan would understand Hansenne to teach that a methyl methacrylate crosspolymer can be provided to otherwise greasy and easily diffusable compositions to impart dryness, in other words a methyl methacrylate crosspolymer can be provided to adsorb oils in oil-based

Art Unit: 1611

compositions to impart dryness. Applicants argue that an ordinarily skilled artisan would not have modified a composition disclosed by Hanna in view of Hansenne because there is no reason to expect that Hanna discloses a composition that is excessively greasy, and there would have been no reason to modify a composition disclosed by Hanna to include the methyl methacrylate crosspolymer disclosed by Hansenne to adsorb oil. Applicants also argue that an ordinarily skilled artisan would not have had the benefit of Applicants' unexpected discovery that the presence of polymethyl methacrylate in a cosmetic composition in the form of a water-in-oil emulsion improves the application properties of the cosmetic composition, including providing superior slip properties to more uniformly distribute the composition over the entire surface to be made up, citing paragraph [0006] of the specification.

This argument is not persuasive. The Examiner disagrees with Applicant's assertions that the ordinarily skilled artisan would have no reason to expect that Hanna discloses a composition that is excessively greasy; one skilled in the art would recognize that water-in-oil emulsions, such as the compositions of Hanna et al, would benefit from the addition of a component which provides the benefits of reducing greasiness and improving dryness, since water-in-oil emulsions tend to have a greasy feel. In response to Applicant's arguments that the ordinarily skilled artisan would have no reason to expect that Hanna discloses a composition that is excessively greasy, the Examiner cites US Patent 4,997,643, which generally teaches that water-in-oil emulsions tend to have a greasy or oily feel (col. 8, lines 58-59). In response to Applicant's arguments regarding improved slip properties, Hanna et al teach that its

Art Unit: 1611

compositions have excellent properties, including long wearing and transfer resistant, and therefore one skilled in the art would reasonably expect the compositions to have good slip properties. Additionally, Applicants have not provided any objective evidence demonstrating that the composition of the claimed invention has unexpectedly improved slip properties over that of the closest prior art.

Applicants argue that the disclosure of Lebreton is unrelated to cosmetic compositions that have an oil phase or are oil-based, such as those disclosed by Hanna and Lebreton. Applicants argue that Lebreton discloses that providing the powdered phase with an acrylic or methacrylic polymer prevents this phase of the lotion from clogging, and the problem of clogging is specific to lotions that consist of an aqueous and a powdered phase. Applicants argue that neither Hanna nor Hansenne disclose compositions that are subject to clogging, the problem Lebreton attempts to solve.

This argument is not persuasive. It has been held that a prior art reference must either be in the field of applicant's endeavor or, if not, then be reasonably pertinent to the particular problem with which the applicant was concerned, in order to be relied upon as a basis for rejection of the claimed invention. See *In re Oetiker*, 977 F.2d 1443, 24 USPQ2d 1443 (Fed. Cir.1992). In this case, although the cited references teach different base compositions (i.e., water-in-oil emulsions vs. aqueous phase only), all the references are directed to the same "pertinent problem" of clogging of solid particulates. Problems of clogging reside with the aggregation of solid particulates, which would include the PMMA particles of Hansenne, and therefore one skilled in the art would be motivated to add the hollow polymethyl methacrylate powder of Lebreton to the

Art Unit: 1611

composition of Hanna and Hansenne, with a reasonable expectation of preventing clogging of the solid particulates therein. Examiner disagrees with Applicant's assertion that the problem of clogging is restricted to lotions that consist of an aqueous and a powdered phase, as the problem of clogging resides with the aggregation of the solid particulates themselves. Additionally, the references of Hanna and Hansenne need not disclose the problem of clogging in order for there to be a benefit with the addition of the powder of Lebreton.

Therefore, it is the Examiner's position that the claims are rendered obvious.

Conclusion

No claims are allowed at this time.

 THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1611

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BARBARA FRAZIER whose telephone number is (571)270-3496. The examiner can normally be reached on Monday-Thursday 9am-4pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila Landau can be reached on (571)272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BSF

/Ashwin Mehta/

Primary Examiner, Technology Center 1600